Anzeige
Mehr »
Login
Mittwoch, 04.12.2024 Börsentäglich über 12.000 News von 680 internationalen Medien
Analysten eilen, um Kursziele zu verdreifachen nach ATHAs neuester Entdeckung
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

GlobeNewswire (Europe)-Archiv vom 19.10.2024

ZeitNachrichten
Sprache: Alle DE EN
LeserMedien
19.10.Nurix Therapeutics, Inc.: Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom's Macroglobulinemia58NX-5948 demonstrated robust clinical activity with objective responses observed in 7 of 9 (77.8%) evaluable Waldenstrom's patients in the ongoing Phase 1a/1b clinical trial Responses are durable and...
► Artikel lesen
19.10.King Faisal Specialist Hospital & Research Centre: KFSHRC Pioneers Cancer Treatment with Breakthrough Therapies and Exceptional Outcomes512RIYADH, Saudi Arabia, Oct. 19, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) is revolutionizing cancer treatment in the region with transformative therapies...
► Artikel lesen
19.10.Tevogen Bio Inc: Tevogen CEO Expresses Gratitude for Unprecedented Public Support of Company's Business Model of Commercial Success Through Patient Accessibility and Reaffirms His Commitment to Share ...439WARREN, N.J., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (Nasdaq: TVGN) is a clinical-stage specialty immunotherapy biotech developing off-the-shelf,...
► Artikel lesen
19.10.Celularity Inc. Receives Notice from Nasdaq; Confirms Intention to File an Appeal121FLORHAM PARK, N.J., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the "Company"), a regenerative medicine company developing and commercializing placental-derived technologies...
► Artikel lesen
19.10.Teqnion AB: Interim report July - September 2024513Short form report TEQ 2024 Q3 Teqnion Group is fighting on in a tough environment with sales increasing 12% but organically it's only up 2%. EBITA margin decreased to 10,9% (11,7%). The profit for...
► Artikel lesen